US OTCQB Trading - Abingdon Health's Growth and Profitability Plan

Proactive Investors
Proactive InvestorsApr 3, 2026

Why It Matters

The OTCQB listing enhances liquidity and gives U.S. investors direct access, supporting Abingdon Health’s growth and profitability strategy.

Key Takeaways

  • Abingdon Health will list on US OTCQB in April.
  • Listing targets Wisconsin investors after opening Madison facility.
  • OTCQB allows US-dollar trading during US market hours.
  • Shares still issued via AIM, enhancing liquidity through dual platform.
  • Expected broader shareholder base and improved market visibility.

Summary

Abingdon Health announced it will commence trading on the U.S. OTCQB market in April, extending its existing listing on the AIM exchange. The move follows the opening of a manufacturing facility in Madison, Wisconsin, a state known for its health‑tech ecosystem, and aims to tap a growing local investor base.

Company executives highlighted that the OTCQB platform enables U.S. investors to buy shares in dollars during U.S. market hours, while the underlying securities continue to be issued on AIM. This dual‑listing structure is expected to improve share liquidity and streamline access for American shareholders.

Chris, the spokesperson, emphasized that “trading on the OTC platform should benefit the liquidity of our shares and the shareholder base as a whole,” noting that trades will flow through to AIM but be executed domestically.

The listing could broaden Abingdon’s investor pool, raise its profile in the U.S. health‑technology sector, and potentially lower capital‑raising costs, positioning the company for accelerated growth and profitability.

Original Description

Abingdon Health reports 45% revenue growth and expects a stronger H2, supported by major contract wins and US expansion. Dr Chris Hand highlights demand for advanced multiplex diagnostics and the company’s push toward profitability.
#AbingdonHealth #Diagnostics #LateralFlow #Biotech #HealthcareInnovation #RapidTesting #MedTech #Pharma #InvestorNews #SmallCaps #AIMMarket #USExpansion #MultiplexTesting #GrowthStocks

Comments

Want to join the conversation?

Loading comments...